Allinaire Therapeutics
Latest round
- Seed
Last raised
- Jan 2017
Total raised
- Undisclosed
Investors
- 3
About Allinaire Therapeutics
Founded in 2016 and headquartered in Cleveland, US, Allinaire Therapeutics LLC is dedicated to the development of therapeutic solutions for pulmonary arterial hypertension and related conditions. The company was established by individuals with a commitment to advancing healthcare through specialized research. Douglas Hay serves as the CEO.Allinaire Therapeutics specializes in developing humanized monoclonal antibodies targeting endothelial monocyte activating polypeptide II (EMAP II), aiming to provide treatments for pulmonary arterial hypertension (PAH) and other cardiopulmonary diseases. The company conducts research on EMAP II, which acts as a non-classical cytokine involved in apoptosis and inflammation.Allinaire Therapeutics generates revenue through partnerships with research institutions and biopharmaceutical companies, focusing on the development of their EMAP II monoclonal antibodies. The company is focused on expanding its product offerings in the therapeutic areas of pulmonary arterial hypertension, chronic obstructive pulmonary disease, and viral-induced acute lung injury. They aim to penetrate markets in North America and Europe with their innovative products, enhancing the treatment landscape for cardiopulmonary diseases.
Who invested in Allinaire Therapeutics
3 investors across 1 round
See all investors in Allinaire Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Jan 26, 2017
Amount
Undisclosed
Investors
Questions about Allinaire Therapeutics
Who invested in Allinaire Therapeutics?
Allinaire Therapeutics has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Allinaire Therapeutics raised?
Allinaire Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Allinaire Therapeutics last raise money?
Allinaire Therapeutics's most recent round on record is a Seed, in Jan 2017.
What does Allinaire Therapeutics do?
Founded in 2016 and headquartered in Cleveland, US, Allinaire Therapeutics LLC is dedicated to the development of therapeutic solutions for pulmonary arterial hypertension and related conditions.
Where is Allinaire Therapeutics headquartered?
Allinaire Therapeutics is headquartered in Cleveland, US.
Which VCs invest in companies like Allinaire Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Allinaire Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Seed
Raising like Allinaire Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.